Molecular Vision: Mookherjee, Mol Vis 2011; 17:2618-2627. Table 6

Table 6. Haplotype frequency of WDR36 in patient and control groups.

Haplotype	Patient category	Frequency in patients (no. of chromosomes)	Frequency in controls (no. of chromosomes)	p-value	OR (95%CI)	Bonferroni corrected p-value
TGGTATGTAA	POAG	0.194 (125)	0.247 (59)	0.077	-	-
	HTG	0.192 (045)		0.159	-	-
	NON-HTG	0.195 (081)		0.118	-	-
TGATGTGCGT	POAG	0.215 (139)	0.198 (47)	0.567	-	-
	HTG	0.181 (042)		0.649	-	-
	NON-HTG	0.233 (096)		0.307	-	-
TAGCACATAA	POAG	0.148 (096)	0.079 (19)	0.007	2.012 (1.206–3.355)	0.168
	HTG	0.170 (039)		0.004	2.329 (1.309–4.141)	0.096
	NON-HTG	0.133 (055)		0.04	1.766 (1.026–3.037)	0.960
CAGCACATAA	POAG	0.056 (036)	0.051 (12)	0.757	-	-
	HTG	0.061 (014)		0.638	-	-
	NON-HTG	0.055 (023)		0.779	-	-

Estimated haplotype frequencies were calculated based on Haploview software. A total of 10 SNPs from phase 1 of the study were used to obtain the haplotype frequencies. The order of SNPs in the haplotype(s) is same as shown in Figure 1. Among 24 different haplotypes obtained from patients and controls, the four haplotypes listed above were found to have a frequency >5% in both patient and control groups. However, no haplotype was found to have any sustainable association with POAG.